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Traditionally, it is believed that white adipose tissues serve as energy storage, heat
insulation, and mechanical cushion, whereas non-shivering thermogenesis occurs in
brown adipose tissue. Recent evidence revealed that adipose tissue secretes many
types of cytokines, called as adipocytokines, which modulate glucose metabolism, lipid
profile, appetite, fibrinolysis, blood pressure, and inflammation. Most of the arteries are
surrounded by perivascular adipose tissue (PVAT). PVAT has been thought to be simply a
structurally supportive tissue for vasculature. However, recent studies showed that PVAT
influences vasodilation and vasocontraction, suggesting that PVAT regulates vascular
tone and diameter. Adipocytokines secreted from PVAT appear to have direct access
to the adjacent arterial wall by diffusion or via vasa vasorum. In fact, PVAT around
atherosclerotic lesions and mechanically-injured arteries displayed inflammatory cytokine
profiles, suggesting that PVAT functions to promote vascular lesion formation. Many
clinical studies revealed that increased accumulation of epicardial adipose tissue (EAT),
which surrounds coronary arteries, is associated with coronary artery disease. In this
review article, we will summarize recent findings about potential roles of PVAT in the
pathogenesis of atherosclerosis, particularly focusing on a series of basic and clinical
studies from our laboratory.
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PERIVASCULAR ADIPOSE TISSUE AND ADIPOCYTOKINES
It has been believed that atherosclerotic process is initiated by endothelial injury, followed by
inflammatory cells infiltration into the subendothelial layer. Thus, inflammation spreads from
the inside toward the outside of the artery (Ross, 1999). On the other hand, it is assumed that
inflammatory process also progresses from the outside toward the inside. Most of the arteries
surrounded by perivascular adipose tissue (PVAT). Aorta has abundant PVAT (Szasz et al.,
2013), while PVAT is not detected around cerebral arteries and microvessels. There is no distinct
borderline between arterial adventitia and PVAT. PVAT has been considered as simply a supporting
organ of vasculature.
In 1991, Soltis and Cassis demonstrated that perivascular adipose tissue significantly influences
vascular responsiveness to contractile stimuli using rat aortic rings with or without surrounding
adipose tissues (Soltis and Cassis, 1991). This study suggested that PVAT potentially serves as a
regulator of vascular responsiveness (Soltis and Cassis, 1991). Recently, adipose tissue have received
a lot of attention as endocrine organ. It was reported that adipocytes secrete numerous kinds of
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inflammatory and anti-inflammatory cytokines, called as
“adipocytokines,” such as tumor necrosis factor (TNF)-α and
adiponectin (Matsuzawa et al., 2004). Analyses of human
samples showed that PVAT around the coronary arteries, like
other adipose tissues, expresses inflammatory cytokines, and
chemokines (Mazurek et al., 2003; Henrichot et al., 2005). It was
also reported that PVAT secretes reactive oxygen spices, nitric
oxide, angiotensin II, and free fatty acid (Szasz et al., 2013).
Adipocytokines secreted from PVAT appear to have direct access
to the adjacent arterial wall via diffusion or vasa vasorum (Sacks
and Fain, 2007; Tanaka et al., 2011) (Figure 1).
INFLUENCE OF PVAT ON ENDOTHELIAL
FUNCTION AND VASCULAR LESION
FORMATION: LESSONS FROM ANIMAL
MODELS
We evaluated whether inflammation in PVAT affects the lesion
formation after a mechanical vascular injury in murine femoral
artery (Takaoka et al., 2009) (Figure 2). Wild-type (C57BL/6)
mice received either a standard chow diet or a high-fat high-
sucrose (HF/HS) diet. The body weight of the wild-type mice
increased by 54% with a HF/HS feeding. The number of
macrophages accumulated in PVAT increased by HF/HS diet.
Expression of adiponectin was down-regulated, while expression
of inflammatory cytokines was up-regulated in PVAT of mice
fed on HF/HS diet. A wire was inserted into the femoral artery
FIGURE 1 | Interaction of perivascular adipose tissue and atherosclerotic plaque. Perivascular adipose tissue (PVAT) secretes inflammatory cytokines that recruit
inflammatory cells into PVAT. PVAT also secrets reactive oxygen spices (ROS), nitric oxide (NO), angiotensin II, and free fatty acid (FFA). Expression of adiponectin is
decreased in PVAT around atherosclerotic plaque. Adipocytokines secreted from PVAT appear to have direct access to the adjacent arterial wall by diffusion or via
vasa vasorum. TNF-α, tumor necrosis factor-α; Ang II, angiotensin II; MCP-1, monocyte chemoattractant protein-1.
of mice to induce endothelial denudation and over-dilatation
of the femoral artery. The changes in cytokine expression in
PVAT around the injured artery was associated with exaggerated
neointima formation at 4 weeks after the injury, suggesting that
PVAT influences pathological vascular remodeling in response to
mechanical vascular injury.
We also investigated an atheroprotective role of healthy PVAT
by removing PVAT in mice fed on a standard diet. Removal of
healthy PVAT markedly enhanced neointima formation, which
was attenuated by transplantation of subcutaneous fat tissues
from the mice fed on a standard diet. The results suggest an
atheroprotective role of healthy PVAT. On the other hand,
transplantation of subcutaneous fat from the obese mice or
visceral fat failed to show atheroprotective effect. To investigate
the local effects of PVAT adiponectin on vascular remodeling,
recombinant adiponectin was delivered locally to the adventitial
space in adiponectin-deficient mice, using gelatin hydrogel.
Four weeks after endovascular injury, neointima formation was
reduced by perivascular delivery of adiponectin. Taken together,
it was suggested that PVAT functions to prevent lesion formation
by secreting atheroprotective adipokines, such as adiponectin.
However, obesity alters adipocytokine expression profiles of
PVAT, resulting in enhanced neointima formation after vascular
injury (Takaoka et al., 2009).
We also reported that mechanical endovascular injury alters
adipocytokine expression in PVAT (Takaoka et al., 2010). A wire
was inserted into the femoral artery of mice to induce endothelial
denudation and over-dilatation. We found that this mechanical
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FIGURE 2 | Obesity-induced inflammatory changes in periadventitial fat enhanced neointimal hyperplasia. (A) Obesity-induced accumulation of inflammatory cells in
periadventitial fat. Immunohistochemical analysis showed accumulation of Mac3-positive macrophages (arrows) within periadventitial fat in obese mice. Scale bar:
50µm. Results are expressed as mean ± SEM. **P < 0.01. M indicates media of femoral artery. (B) Expression of mRNA in periadventitial fat around femoral artery
from STD (standard diet) (n = 6) and HF/HS (high fat/high sucrose diet) WT C57BL6 mice. Expression level was assessed by real-time PCR normalized to each
GAPDH level. Results are expressed as means ± SEM. *P < 0.05, **P < 0.01. (C) Hematoxylin/eosin-stained sections of femoral arteries from mice fed on STD or
HF/HS diet 4 weeks after endovascular injury. Arrows indicate internal elastic lamina. Scale bar: 100µm. Morphometric analysis of injured femoral arteries in lean (n =
7) and obese (n = 6) mice 4 weeks after wire-induced injury. Results are expressed as means ± SEM. **P < 0.01. All figures are cited from the reference (Takaoka
et al., 2009) with permission.
injury up-regulated inflammatory cytokines and down-regulated
adiponectin in PVAT. These changes were attenuated in TNF-α
knockout mice, suggesting that TNF-α is important to transmit
endovascular injury to adipocytokine changes in PVAT (Takaoka
et al., 2010).
Consistent with our studies, others reported that PVAT plays
a role in the pathogenesis of vascular lesion formation. Ketonen
et al. reported that obesity-induced endothelial dysfunction is
caused by increased oxidative stress and enhanced expression of
inflammatory cytokine in PVAT (Ketonen et al., 2010). Manka
et al. reported that transplantation of PVAT from obese mice
to low-density lipoprotein receptor knockout mice enhanced
lesion formation with increased inflammatory cell infiltration
and pathological angiogenesis in adventitia. Theses pathological
effects of PVAT transplantation was attenuated when PVAT
from monocyte chemoattractant protein-1 (MCP-1)-deficient
mice was transplanted. These results suggest that PVAT
promotes vascular lesion formation through MCP-1-dependent
mechanisms (Manka et al., 2014). These animal studies indicate
that obesity increases expression of inflammatory adipocytokines
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in PVAT, leading to endothelial dysfunction and enhanced
vascular lesion formation.
POSSIBLE ROLES OF EPICARDIAL
ADIPOSE TISSUE IN THE PATHOGENESIS
OF HUMAN CORONARY ARTERY DISEASE
Epicardial adipose tissue (EAT) is assumed to secrete abundant
cytokines to the adjacent coronary artery (Sacks and Fain,
2007). For example, in the patients undergoing coronary
artery bypass graft (CABG) surgery, it was reported that EAT
abundantly expressed interleukin (IL)-1β, IL-6, TNF-α, and
MCP-1 compared to their subcutaneous adipose tissue (Mazurek
et al., 2003). Baker et al. reported that the expression of
adiponectin mRNAwas significantly lower in EAT than in gluteal
and abdominal adipose tissues (Baker et al., 2006).
However, it remains to be elucidated whether the potential
role of chronic inflammation in EAT plays a role in the
pathogenesis of coronary artery disease (CAD). Therefore, we
analyzed EAT obtained during cardiac surgery (Hirata et al.,
2011a,b). EAT and subcutaneous adipose tissue (SCAT) were
obtained from 38 CAD patients undergoing CABG and 40
non-CAD patients undergoing valvular surgery (Hirata et al.,
2011b). Expressions of IL-6 and TNF-α were significantly
increased in EAT of the CAD group compared to that of the
non-CAD group. There was no significant difference between
the CAD and the non-CAD groups in the expression of
adipocytokines in SCAT. To investigate the mechanisms by
which expression of inflammatory cytokines is elevated in EAT
of the CAD patients, we performed immunohistochemistry
against CD68, a marker for all types of macrophages, CD11c,
a marker for inflammatory M1 macrophage (Lumeng et al.,
2007), and CD206, a marker for anti-inflammatory M2
macrophage (Bourlier et al., 2008) (Figure 3). CD68 positive
macrophages were significantly increased in EAT of the CAD
group. The ratio of CD11c/CD68-positive cells was significantly
increased, and the ratio of CD206/CD68-positive cells was
significantly decreased in EAT in the CAD group. These
data demonstrate relative increase of M1 macrophages and
relative decrease of M2 macrophages in EAT in the CAD
group. The ratio of M1/M2 macrophages showed positive
correlation with the severity of CAD as determined by
Gensini score (Gensini, 1983). These results suggested that
the chronic inflammation and macrophage polarization in
EAT would play a pathological role in human coronary
atherosclerosis.
Recently, it was reported that the expression of omentin was
detected in EAT. Omentin, also known as interectin-1, is one
of the recently identified adipocytokines (Harada et al., 2016).
Omentin is expressed abundantly in omentum adipose tissue
and is considered to have cardiovascular protective effects like
adiponectin. It is known that omentin expression decreases in
the milieus of diabetes mellitus or obesity (Shibata et al., 2017).
Harada et al. analyzed EAT and SCAT from 15 non-obese CAD
patients and 10 non-obese and non-CAD patients. Omentin
expression increased in the EAT of non-obese CAD patients,
despite a decrease in plasma levels. These results indicated that
FIGURE 3 | Macrophage infiltration in human epicardial adipose tissue and subcutaneous adipose tissue. (A) Representative images of immunohistochemical staining
showing accumulation of CD68-, CD11c-, and CD206-positive cells in epicardial adipose tissue (EAT) of coronary artery disease (CAD) patient. Scale bar = 100µm.
(B) Cell count of accumulating macrophages. Each point represents the cell count of infiltrating macrophages (/mm2). Bar indicates mean. *p < 0.05. SCAT,
subcutaneous adipose tissue. All figures are cited from the reference (Hirata et al., 2011b) with permission.
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omentin expression in EAT may play a certain role in the
pathogenesis of CAD (Harada et al., 2016).
EPICARDIAL ADIPOSE TISSUE VOLUME
AND CORONARY ARTERY DISEASE
More than 200 years ago, an autopsy report of the case of
a patient, who died in 1801, already described that CAD
was combined with unusual accumulation of fat about the
heart (Warren, 1962). Recently, many groups including us
suggested that CAD is associated with increased EAT volume
(Dagvasumberel et al., 2012). EAT volume can be quantified by
coronary CT, echocardiography and MRI (magnetic resonance
imaging). Konishi et al. measured “pericardial adipose tissue”
volume by 64-slice CT, and suggested that CAD is more highly
associated with pericardial fat volume than abdominal obesity
(Konishi et al., 2010). Other studies also suggested that EAT
volume may predict the severity of coronary atherosclerotic
lesions and the clinical prognoses (Dagvasumberel et al., 2012).
Moreover, a recent study indicated that EAT volume predicts
fatal and non-fatal cardiac events independently of the classical
coronary risk factors (Mahabadi et al., 2013).We also investigated
the impact of EAT volume on CAD (Dagvasumberel et al.,
2012). Multivariate analysis indicated that EAT volume index
[EAT volume/body surface area (BSA)] were significant CAD
predictors in men, whereas BMI, age, presence of hypertension,
diabetes mellitus, and hyperlipidemia were not associated with
the presence of CAD.
Previous studies suggested that increased visceral adipose
tissue (VAT) is associated with CAD. For example, the
prospective long-term follow-up of the FraminghamHeart Study
showed that VAT was an independent predictor of incident
of cardiovascular disease (Britton et al., 2013). Accumulating
evidence suggests that inflammatory cells can be observed in
VAT than in SCAT and that VAT secretes more inflammatory
adipocytokines than SCAT (Ibrahim, 2010). It is also suggested
that VAT adipocytes plays more important roles in the
pathogenesis of insulin resistance than SCAT adipocytes does
(Ibrahim, 2010). Thus, it is likely that VAT influences vascular
function and atherosclerosis than SCAT does.
We collected EAT and SCAT from 50 CAD patients and
50 non-CAD patients who underwent elective cardiac surgery.
We evaluated the polarity of the accumulated macrophages
in adipose tissue by immunohistochemical staining with the
antibodies for CD68, CD11c, and CD206 and compared them
with EAT volume index (Figure 4) (Shimabukuro et al., 2013).
We found that EAT volume index was a significant prognostic
factor to predict CAD. There were positive correlations between
EAT volume index and the numbers of CD68 and CD11c positive
M1 macrophage, and the expressions of inflammatory cytokines
such as IL-1β, and negatively correlated with adiponectin
expression in EAT (Shimabukuro et al., 2013). A multivariate
analysis model revealed that number of CD68 (+) cells and
IL-1β, and adiponectin expression in EAT strongly predicted
CAD. These results indicated that EAT volume, macrophage
infiltration, and adipocytokine signals in EAT are closely
associated with CAD and that EAT volume and adipocytokine
imbalance play critical roles in the pathogenesis of human
coronary atherosclerosis.
Recent reports suggested that EAT accumulation is associated
with not only coronary artery disease but also atrial fibrillation
(AF) (Soeki and Sata, 2012). In Framingham heart cohort, EAT
volume was measured by CT in 3217 subjects, and it was
suggested that EAT volume was an independent risk factor of
AF after adjusting other risk factors such as hypertension, PR
interval, and body mass index (BMI) (Thanassoulis et al., 2010).
Another study demonstrated that peri-atrial EAT volume was
associated with new-onset AF in patients with CAD, independent
of enlargement of the left atrium (Nakanishi et al., 2012). It is
assumed that inflammatory cytokines secreted from peri-atrial
EAT promote fibrotic remodeling of atrial myocardium, leading
to AF (Hatem et al., 2016).
HOW TO EVALUATE EPICARDIAL
ADIPOSITY?
Although many groups have investigated correlation between
the EAT volume and coronary atherosclerotic lesions, there
might be a confusion in definition of fat depots around the
heart (Yamada and Sata, 2015). EAT, or subepicardial adipose
tissue, located inside the parietal pericardium, have a direct
contact with coronary artery (Figure 5). On the other hand,
adipose tissue located outside the parietal pericardium is called as
paracardial adipose tissue (PAT). PAT is also called as thoracic or
intrathoracic adipose tissue. There is a difference in the definition
of “pericardial adipose tissue.” In some studies, PAT was
described as “pericardial adipose tissue,” whereas EAT or EAT
together with PAT were described as “pericardial adipose tissue”
in other studies (Yamada and Sata, 2015). EAT shares coronary
circulation with cardiac myocardium, while PAT is perfused by
non-coronary source. Thus, EAT and PAT are distinct fats with
different impacts on coronary atherosclerosis (Yamada and Sata,
2015). We would like to define that “pericardial adipose tissue”
means “epicardial adipose tissue” plus “paracardial adipose
tissue.”
To evaluate EAT accumulation, different groups use EAT
volume (Konishi et al., 2010; Mahabadi et al., 2013) or EAT
volume index, which is EAT volume divided by BSA. We
found that the EAT volume was higher in men than in
women, but the mean EAT volume/height and EAT volume/BSA
were comparable (Dagvasumberel et al., 2012). Therefore, it is
likely that EAT volume index might be a preferable parameter
(Shimabukuro et al., 2013).
El Khoudary et al. assessed whether volumes of heart fat
depots (EAT and PAT) were associated with coronary artery
calcification (CAC) in women at midlife and whether these
associations were modified by menopausal status and estradiol
levels (El Khoudary et al., 2017). Volumes of PAT and EAT
increased after menopause. Of note, estradiol decline was
associated with PAT volume, but not EAT volume, suggesting that
menopause has something to do with PAT accumulation. CAC
measures were associate with EAT volume. Menopausal status or
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FIGURE 4 | Correlation between the EAT volume index and the number of CD68+, CD11c+, and CD206+ cells in EAT. The EAT volume index was positively
correlated with the numbers of CD68+, and CD11c+ cells in EAT in the patients who underwent non-coronary (◦) or coronary (•) surgery. Liner regression analysis
was made in a combined group, including non-coronary artery disease (CAD) and CAD subjects. R and P-values are shown. EATV index, epicardial adipose tissue
volume index. All figures cited from the reference (Shimabukuro et al., 2013) with permission.
FIGURE 5 | Identification of epicardial adipose tissue and paracardial adipose tissue. Identification of epicardial adipose tissue and paracardial adipose tissue by
echocardiography (Left) and contrast enhanced 320-slice multi-detector computed tomography (Right). The asterisks (*) indicate left descending coronary artery.
“Pericardial adipose tissue” includes both epicardial adipose tissue (located within or deep into the pericardium) and paracardial adipose tissue (located superficial to
the pericardium). Sometimes, pericardial adipose tissue is referred to as paracardial adipose tissue. All figures cited from the reference (Yamada and Sata, 2015)
without modification.
estradiol did not modify this association. In contrast, menopausal
status significantly modified association between PAT and CAC
measures. It was reported that PAT might be a risk factor for
coronary artery disease in menopausal women. It was suggested
that PAT depot need to be monitored and would be a target for
intervention in women at midlife (El Khoudary et al., 2017).
Many groups measured EAT thickness using echo-
cardiography and reported that EAT thickness was greater
in CAD patients than in non-CAD patients (Iacobellis, 2015).
Recently, we developed a new method to evaluate EAT thickness
(Hirata et al., 2015). We evaluated EAT thickness at anterior
interventricular groove (EAT-AIG) and at anterior right ventricle
(EAT-RV) of 311 patients by echocardiography using a high
frequency linear probe. EAT-AIG had a strong correlation with
EAT volume evaluated by coronary CT. Both EAT-AIG and
EAT-RV of CAD patients were greater than those of non-CAD
patients. EAT-AIG was more strongly correlated with CAD
as determined by the receiver operating characteristics curve
analysis. It was suggested that we may be able to predict CAD
with high sensitivity and specificity by evaluating EAT thickness
by the non-invasive echocardiography using the high frequent
linear probe (Hirata et al., 2015).
Nerlekar at al. performed meta-analysis to assess the
association between EAT and high-risk plaque (HRP) (Nerlekar
et al., 2017). Nine studies (n = 3,772 patients) were included
with seven measuring EAT volume by CT and two measuring
EAT thickness by echocardiography. Increase in EAT volume or
thickness was associated with the presence of HRP. Increasing
EAT volume has a significant association with HRP. However,
EAT thickness had no significant association with HRP. This
analysis included only two studies evaluating EAT thickness by
echocardiography. Further investigation is required to establish
clinical significance of evaluating EAT thickness to predict the
existence of HRP.
Besides coronary CT and echocardiography, it was reported
that EAT volume can be evaluated by MRI (Levelt et al., 2016).
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There is no standard method to evaluate EAT volume to predict
coronary atherosclerosis disease. It is hoped that EAT can be
evaluated precisely and easily using appropriate modalities.
CAN PVAT BE REDUCED TO PREVENT
CARDIOVASCULAR EVENTS?
It is very important to clarify whether modification of life-
style or medication can reduce PVAT, leading to phenotypic
improvement of inflammatory PVAT. It was reported that EAT
was decreased by aerobic exercise for 12 weeks in obese middle-
aged men (Kim et al., 1985). Interestingly, reduction in EAT
volume showed linear correlation with reduction in VAT volume
(Kim et al., 1985).
In a sub-analysis of BELLES (Beyond Endorsed Lipid
Lowering with Electron Beam Tomography Scanning) trial, in
which the effect of the moderate and the aggressive doses
of statin therapy to coronary calcification were tested in 615
hyperlipidemic post-menopausal women, EAT volume was
measured by CT in the intensive therapy group (atorvastatin
80mg) and the moderate therapy group (pravastatin 40mg).
One year later, reduction of EAT volume was observed in the
intensive and the moderate therapy groups. Decrease in EAT
volumewas statistically significant in the intensive therapy group,
but not in the moderate therapy group. Interestingly, EAT
volume reduction showed no correlation with the degree of
lipid lowering. These results suggested that, in post-menopausal
women, statin therapy decreased EAT volume especially in the
intensive therapy group and that the effect of statin was not
associated with the LDL lowering effect. Anti-inflammatory
pleiotropic effects of statin might be related to this effect
(Alexopoulos et al., 2013).
Recently, it was reported that sodium-glucose co-transporter
2 (SGLT2) inhibitors (ipragliflozin, luseogliflozin, and
canagliflozin) reduced the EAT (Bouchi et al., 2017; Fukuda
et al., 2017; Yagi et al., 2017) as well as the abdominal visceral
fat (Tosaki et al., 2017) in type 2 diabetes patients. Recent
randomized clinical trials showed that use of SGLT2 inhibitors
(canagliflozin and empagliflozin) decreases mortality and
morbidity of cardiovascular diseases in diabetic patients
(Zinman et al., 2015; Neal et al., 2017). If SGLT2 inhibitors
can decrease EAT volume as well as other adipose tissues, it is
assumed that reduction in EAT could lead to cardiovascular
protective effects by SGLT2 inhibitors, which have been proved
by recent randomized clinical trials (Heerspink et al., 2016;
Rajasekeran et al., 2016).
It remains to be clarified whether the decrease of EAT by
any therapeutic interventions can inhibit progression of coronary
lesions or the occurrence of coronary events. Further studies will
clarify whether reduction in EAT volume could be a therapeutic
target to prevent cardiovascular events.
CONCLUSIONS
PVAThas been considered to secrete humoral factors, influencing
the function and the lesion formation of the adjacent artery.
EAT volume can be measured by CT, echocardiography and
MRI, which are commonly used in clinical practices. Numerous
imaging studies suggested that increased EAT volume is
associated with CAD. Almost all the data presented is correlative.
It remains to be elucidated whether the reduction of EAT
volume would be effective in prevention of cardiovascular events.
Future studies will clarify more in detail the roles of PVAT in
the pathogenesis of CAD. EAT would be a useful biomarker
in the diagnosis of CAD and would be a good therapeutic
target.
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